The ACCORD study: The devil is in the details

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.

Original languageEnglish (US)
Pages (from-to)81-84
Number of pages4
JournalMetabolic Syndrome and Related Disorders
Volume9
Issue number2
DOIs
StatePublished - Apr 1 2011

Fingerprint

Blood Pressure
Fenofibrate
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
Blood Glucose
Therapeutics
Hypertension

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

The ACCORD study : The devil is in the details. / Siegel, David; Swislocki, Arthur L.

In: Metabolic Syndrome and Related Disorders, Vol. 9, No. 2, 01.04.2011, p. 81-84.

Research output: Contribution to journalArticle

@article{ae7d90c344124e54b4fc955f03bf0abd,
title = "The ACCORD study: The devil is in the details",
abstract = "The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.",
author = "David Siegel and Swislocki, {Arthur L}",
year = "2011",
month = "4",
day = "1",
doi = "10.1089/met.2010.0119",
language = "English (US)",
volume = "9",
pages = "81--84",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - The ACCORD study

T2 - The devil is in the details

AU - Siegel, David

AU - Swislocki, Arthur L

PY - 2011/4/1

Y1 - 2011/4/1

N2 - The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.

AB - The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.

UR - http://www.scopus.com/inward/record.url?scp=79953100939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953100939&partnerID=8YFLogxK

U2 - 10.1089/met.2010.0119

DO - 10.1089/met.2010.0119

M3 - Article

C2 - 21166575

AN - SCOPUS:79953100939

VL - 9

SP - 81

EP - 84

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 2

ER -